Navigation Links
New Data: Cholesterol Management Analysis of Upsher-Smith's Slo-Niacin(R) Tablets in Combination with Lipitor(R)
Date:11/16/2009

MAPLE GROVE, Minn., Nov. 16 /PRNewswire/ -- Results of the SLIM Study ("Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia") were recently published in the Journal of Clinical Lipidology. The objective was to study the lipid and anti-inflammatory effects of Slo-Niacin® 1.5 g/day and Lipitor (atorvastatin calcium) 10 mg/day, given alone and then together in persons with features of combined hyperlipidemia, high triglycerides, low high-density lipoproteins (HDL - "good cholesterol") and above average low-density lipoproteins (LDL - "bad cholesterol"). The result of the combination therapy was a marked decrease in triglycerides and LDL and a significant increase in HDL.1

"The efficacy of controlled-release Slo-Niacin® has never been studied with Lipitor," explained Dr. Robert Knopp, main author of the SLIM Study, professor of medicine at Harborview Medical Center and director of the Northwest Lipid Research Clinic. "The findings of the SLIM Study provide further foundation to the 20 years of experience with Slo-Niacin®."

Heart disease and stroke develop when elevated levels of LDL circulate in the blood and build up in the walls of the arteries that feed the heart and brain. Elevated triglycerides further this process. The result is plaque, a thick, hard deposit that narrows arteries and makes them less flexible. This condition is known as atherosclerosis. HDL, on the other hand, protects the blood vessels by carrying cholesterol away from the arteries and back to the liver, where it is passed from the body.2

About the study

In this trial, forty-two men and women ages 21 to 75 years with LDL levels greater than 130 mg/dL and HDL less than 45 mg/dL (women less than 55 mg/dL) were randomized to three months of Lipitor 10 mg/day or Slo-Niacin® titrated to 1.5 g/day. The al
'/>"/>

SOURCE Upsher-Smith Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
2. Synvista Collaboration Demonstrates in Preclinical Studies the Mechanism for Defective Cholesterol Transport in Patients with Diabetes
3. Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary
4. New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol
5. Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
6. People With Diabetes May Have All-Natural Citrus Supplement To Help Lower Blood Glucose and Cholesterol Levels
7. Blueberry-Supplemented Diet Shows Promise in Lowering Cholesterol in Animal Trials
8. Fish Oil and Red Yeast Rice Studied for Lowering Blood Cholesterol
9. VAP Cholesterol Test Helps Reveal Association Between Adiponectin Levels and Atherosclerosis
10. Leading Cardiologist Joins Ontario Research Firm to Conduct New Clinical Trial on the Effect of Pantethine on Cholesterol Levels
11. Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2010)... Hanger Orthopedic Group, Inc. (NYSE: HGR ... of operations for the year ended December 31, 2009 ... Company plans to issue a press release announcing the results ... Wednesday, February 10, 2010 , after the close of ... 9:00 a.m., EST , on Thursday, February 11, ...
(Date:2/8/2010)... Heska Corporation (Nasdaq: HSKA ) announces the following Webcast: ,, (Logo: ... What: Heska Corporation Invites You to ... Year-End 2009 Earnings Conference Call on the Web, ... February 22, 2010 @ 1:00 p.m. (MST), , ... Earnings Call , ...
(Date:2/8/2010)... Fla. , Feb. 8 ... has signed an advertising contract with SkyMall Inc. ... is distributed in major airlines seat pockets. SkyMall ... copies. The advertisement featuring the MedFlash ® ... opposite the table of contents in the front ...
Breaking Medicine Technology:Hanger Orthopedic Group, Inc. Announces 2009 Year-End Earnings Release Conference Call 2Webcast Alert: Heska Announces Fourth Quarter and Year-End 2009 Earnings Conference Call Webcast 2Connectyx Announces MedFlash(R) Advertising Contract with SkyMall Inc. 2Connectyx Announces MedFlash(R) Advertising Contract with SkyMall Inc. 3Lilly Confirms Date and Conference Call For Fourth Quarter and Full Year 2009 Financial Results Announcement 7400 1Lilly Confirms Date and Conference Call For Fourth Quarter and Full Year 2009 Financial Results Announcement 7400 2Haiti Relief Site Now in Portuguese 64732 1Haiti Relief Site Now in Portuguese 64732 2Haiti Relief Site Now in Portuguese 64732 3President Obama Tasks Former Presidents Bush and Clinton with Fundraising for Haiti Recovery 64731 1President Obama Tasks Former Presidents Bush and Clinton with Fundraising for Haiti Recovery 64731 2President Obama Tasks Former Presidents Bush and Clinton with Fundraising for Haiti Recovery 64731 3
... 26 Pharmacopeia,(Nasdaq: PCOP ), an innovator ... therapeutics, today announced the completion of recruitment,in the ... (DARA),the company,s lead internal product candidate. The objective ... is to,evaluate the efficacy and safety of 200 ...
... Australia, Feb. 26 Bionomics Limited (ASX:,BNO) today announced ... Phase I trial of its anti-cancer drug, BNC105., ... patients with,advanced cancer. Patients will be treated with BNC105 ... over two cycles. The trial will be conducted at ...
Other Medicine Technology:Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA) 2Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA) 3Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA) 4Treatment of First Patient in Phase I Clinical Trial of Bionomics' Anti-Cancer Drug BNC105 2Treatment of First Patient in Phase I Clinical Trial of Bionomics' Anti-Cancer Drug BNC105 3
(Date:2/9/2010)... Cancer Institute and the Sanford-Burnham Medical Research Institute ... wholly owned member of the Roche group, and ... manufacture, develop and market human monoclonal antibodies to ... These viruses include the strains for the current ... have a non-exclusive right to manufacture, develop and ...
(Date:2/9/2010)... Rhonda Roby , ... University of North Texas Center for Human Identification ... instrumental in recently identifying three murder victims of the ... ,, The Chilean government contacted Roby in ... audit team of the victims, identification program for Patio ...
(Date:2/9/2010)... State University has launched the nation,s first comprehensive ... counterfeiting- which the FBI has called "the crime ... products- from pharmaceuticals to food additives to auto ... in global trade and has a major impact ... and national security. Terrorist and other organized crime ...
(Date:2/9/2010)... -- The first results from a large-scale study ... countries reveal that a high percentage of medicines ... and thus may contribute to the growth of ... most virulent form of malaria. The findings, released ... (PQM) Program, a USAID-funded program implemented by the ...
(Date:2/9/2010)... , Feb. 9 The Quantum Foundation ... the School District of Palm Beach County that ... fit. The Robert Wood Johnson Foundation (RWJF) recently announced a ... and access to affordable healthy foods for children and families ... communities. Based on a rigorous selection process that drew ...
Breaking Medicine News(10 mins):Health News:UNT Health Science Center's Roby Helps Identify Bodies of Chile's Patio 29 2Health News:UNT Health Science Center's Roby Helps Identify Bodies of Chile's Patio 29 3Health News:MSU launches first anti-counterfeiting research program 2Health News:MSU launches first anti-counterfeiting research program 3Health News:One-third of antimalarial medicines sampled in 3 African nations found to be substandard 2Health News:One-third of antimalarial medicines sampled in 3 African nations found to be substandard 3Health News:Planting Seeds to Fight Childhood Obesity 2
... is an early or predisposing event in the pathogenesis ... research which appears online on September 23 in the ... Myelodysplastic syndrome is a heterogeneous group of diseases ... hematopoietic lineages, clonal evolution and a tendency to progress ...
... been used widely in the treatment of hypertension ... hypertension guidelines. Moreover, after myocardial infarction and in ... blockers prevents re-infarction, hospitalisation for heart failure, and ... that atenolol is not very effective in hypertension. ...
... of bleeding from solid abdominal organs has been traditionally ... which has latelybeen recognized as detrimental. // Although there ... hemorrhage, bleeding is still the direct cause of death ... ,There is a continuous search for the "magical drug" ...
... has produced two Anti-retrovirals which can be used ... Nevirapine and Zidovudine is produced by CMSI in ... two drugs were officially released by Sebastian Ouseperamppil, ... which could maintain the quality control and Research ...
... Reddy Union Minister of Information, Broadcasting and Culture, India ... public regarding the prevention and treatment of HIV infections. ... social relevance. The media could play an important role ... the different broadcasting tools such as radio, websites, SMS, ...
... study, published in the October issue of the journal ... immune system abnormalities, including reduced levels of NKT cells, ... cells in the liver regulate production of cytokines, which ... may contribute to obesity -related liver disease. ,The ...
Other Medicine News:Health News:Evidence against use of Beta blockers as first choice in the treatment of primary hypertension 2Health News:Aprotinin in the treatment of hemorrhagic shock trauma patients 2Health News:Obesity As A Contributor To Liver Disease 2
... advanced glass technologies and designs, the ... magnification views of the posterior pole. ... image quality previously unattainable with the ... more detailed and comprehensive views, helping ...
... autoimmune testing feature single-well ANA screen and ... reflex tests including dsDNA, and 6 individual ... (La), Scl-70 and Jo-1. In addition, our ... of products for Cardiolipins (IgA, IgG, IgM), ...
... ELISA products for autoimmune testing feature single-well ... well as specific reflex tests including dsDNA, ... SS-A (Ro), SS-B (La), Scl-70 and Jo-1. ... a full line of products for Cardiolipins ...
... Peel PRESTIGE system was designed with advanced ... of the most demanding skin care practice. ... the Parisian Peel PRESTIGE machine is designed ... to offer maximum versatility and full abrasion ...
Medicine Products: